Effects and problems of continuous infusion of epoprostenol for patients with primary pulmonary hypertension

Internal Medicine

Volumn 41, Issue 10, 2002, Pages 784-788

  Takahashi, Tohru ^a   Sakuma, Masahito ^a   Ikeda, Jun ^a   Nawata, Jun ^a   Demachi, Jun ^a   OsamuKitamukai, ^a   Shirato, Kunio ^a  

^a TOHOKU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

6 minute walking distance; Brain natriuretic peptide; Cardiac output; Hemodynamics; Out patient; Vascular resistance

Indexed keywords

ATRIAL NATRIURETIC FACTOR; BERAPROST; BRAIN NATRIURETIC PEPTIDE; CALCIUM ANTAGONIST; PROSTACYCLIN;

ABDOMINAL DISCOMFORT; ADULT; ARTHRALGIA; ARTICLE; BLEEDING TENDENCY; BONE PAIN; CLINICAL ARTICLE; CONTROLLED STUDY; DIARRHEA; DRUG EFFECT; EXERCISE TEST; FEMALE; FUNCTIONAL ASSESSMENT; HEART FAILURE; HEART OUTPUT; HEMODYNAMICS; HUMAN; JAW; LUNG ARTERY PRESSURE; LUNG HEMORRHAGE; LUNG TRANSPLANTATION; LUNG VASCULAR RESISTANCE; MALE; MORTALITY; MYALGIA; PROTEIN BLOOD LEVEL; PULMONARY HYPERTENSION; SYMPTOMATOLOGY; SYSTEMIC VASCULAR RESISTANCE; TREATMENT INDICATION; WALKING;

EID: 0036808874     PISSN: 09182918     EISSN: None     Source Type: Journal    
DOI: 10.2169/internalmedicine.41.784     Document Type: Article

References (17)

1. D'Alonzo GE, Barst RJ, Ayres SM, et al. Survival in patients with primary pulmonary hypertension. Ann Intern Med 115: 343-349, 1991.
2. Rich S, Dantzker DR, Ayres SM, et al. Primary pulmonary hypertension. Ann Intern Med 107: 216-223, 1987.
3. Okada O, Tanabe N, Yasuda J, et al. Prediction of life expectancy in patients with primary pulmonary hypertension. A retrospective nationwide survey from 1980-1990. Intern Med 38: 12-16, 1999.
4. Rich S, McLaughlin VV. The effects of chronic prostacyclin therapy on cardiac output and symptoms in primary pulmonary hypertension. J Am Coll Cardiol 34: 1184-1187, 1999.
5. Hinderliter AL, Willis PW, Barst RJ, et al. Effects of long-term infusion of prostacyclin (Epoprostenol) on echocardiographic measures of right ventricular structure and function in primary pulmonary hypertension. Circulation 95: 1479-1486, 1997.
6. McLaughlin VV, Genthner DE, Panella MM, Rich S. Reduction in pulmonary vascular resistance with long-term epoprostenol (prostacyclin) therapy in primary pulmonary hypertension. N Engl J Med 338: 273-277, 1998.
7. Rubin LJ. Primary pulmonary hypertension. N Engl J Med 336: 111-117, 1997.
8. Date H. Current status and future of lung transplantation. Intern Med 40: 87-95, 2001.
9. Jones DK, Higenbottam TW, Wallwork J. Treatment of primary pulmonary hypertension with intravenous epoprostenot (prostacyclin). Br Heart J 57: 270-278, 1987.
10. Barst RJ, Maislin G, Fishman AP. Vasodilator therapy for primary pulmonary hypertension in children. Circulation 99: 1197-1208, 1999.
11. Takahashi T, Sakuma M, Nawata J, et al. A case with severe right heart failure due to primary pulmonary hypertension treated by epoprostenol and cardiotonic agent. Ther Res 21: 2032-2034, 2000.
12. Wharton J, Davie N, Upton PD, Yacoub MH, Polak JM, Morrell NW. Prostacyclin analogues differentially inhibit growth of distal and proximal human pulmonary artery smooth muscle cells. Circulation 102: 3130-3136, 2000.
13. Nagaya N, Nishikimi T, Uematsu M, et al. Plasma brain natriuretic peptide as a prognostic indicator in patients with primary pulmonary hypertension. Circulation 102: 865-870, 2000.
14. Nagaya N, Nishikimi T, Okano Y, et al. Plasma brain natriuretic peptide levels increase in proportion to the extent of right ventricular dysfunction in pulmonary hypertension. J Am Coll Cardiol 31: 202-208, 1998.
15. Miyamoto S, Nagaya N, Satoh T, et al. Clinical correlates and prognostic significance of six-minute walk test in patients with primary pulmonary hypertension: comparison with cardiopulmonary exercise testing. Am J Respir Crit Care Med 161: 487-492, 2000.
16. Rubin LJ, Groves BM, Reeves JT, Frosolno M, Handel F, Cato AE. Prostacyclin-induced acute pulmonary vasodilation in primary pulmonary hypertension. Circulation 66: 334-338, 1982.
17. Rubin LJ, Mendoza J, Hood M, et al. Treatment of primary pulmonary hypertension with continuous intravenous prostacyclin (epoprostenol): results of randomized trial. Ann Intern Med 112: 485-491, 1990.